Home » Newsletters » BioWorld Science

BioWorld Science

June 13, 2005

View Archived Issues

Antiarthritic effects of dRK6

New generation antifolate drugs show promise for methotrexate-resistant RA

Novel PDE3/4 inhibitors with bronchodilator and antiinflammatory properties reported

Asoprisnil recruits coactivators to target gene promoters

AMG-641 shows promising preclinical results for hyperparathyroidism treatment

Update on the antitumor effects of AMN-107 in hematological malignancies

Eprosartan shows efficacy in the prevention of secondary stroke

Promising clinical results reported for Cotara in malignant glioma

No abuse potential found with ramelteon in humans

Agomelatine improves the sexual function of male depressed patients

Target enrollment reached in phase II wet AMD study of Evizon

New data on the use of TDM to optimize MMF therapy in kidney transplant

AMDL receives nonsubstantial equivalence letter from the FDA

Surface Logix studies selective oral PDE5 inhibitor in phase I trial

Biotest's BT-061 found effective in refractory RA

AnGes and MedGel to develop innovative antiinflammatory drugs

Anastrozole studied for postmenopausal women with metastatic breast cancer

Preclinical study for Avantogen-codeveloped herpes vaccine

PhosLo studied in chronic kidney disease patients

Private investment to fund Osiris' three clinical programs

Positive preclinical results for two new Novavax compounds

DailyDrugNews.com headline e-mail alerts now contain links

Diovan receives E.U. marketing authorization for heart failure indication

Actemra, world's first drug for Castleman's disease launched in Japan

Temodal approved in Europe for newly diagnosed glioblastoma multiforme

Alteon discontinues systolic hypertension study of alagebrium

Japanese launch of Amnolake for APL

New therapeutics for cancer disclosed in recent patents

New treatments for obesity and other metabolic disorders disclosed